Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | synuclein, alpha (non A4 component of amyloid precursor) | Starlite/ChEMBL | No references |
Homo sapiens | polo-like kinase 1 | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | serine:threonine protein kinase PLK1 | 0.0114 | 1 | 1 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.3302 | 0.3025 |
Echinococcus granulosus | serine:threonine protein kinase PLK1 | 0.0114 | 1 | 1 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0114 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3302 | 0.3302 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3302 | 0.3302 |
Giardia lamblia | Kinase, PLK | 0.0114 | 1 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.3302 | 0.3025 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0114 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.3302 | 0.3025 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 0.5 |
Trypanosoma brucei | polo-like protein kinase | 0.0114 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3302 | 0.3302 |
Onchocerca volvulus | Serine\/threonine kinase homolog | 0.0114 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3302 | 0.3302 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.3302 | 0.3025 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.3302 | 0.3025 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0114 | 1 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 0.5 |
Leishmania major | protein kinase, putative,polo-like protein kinase, putative | 0.0114 | 1 | 0.5 |
Loa Loa (eye worm) | PLK/PLK1 protein kinase | 0.0114 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3302 | 0.3302 |
Entamoeba histolytica | serine/threonine protein kinase, putative | 0.0114 | 1 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0114 | 1 | 0.5 |
Brugia malayi | RNA binding protein | 0.0076 | 0.3302 | 0.3025 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 7.5193 uM | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.